3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
11
Gastrointestinal
5
Thoracic
4
Sarcoma
2
Gynecologic
2
Dermatologic
2
Breast
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Classical hematology
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Differentiated Thyroid Cancer
2
Adenoma, Islet Cell
2
Tuberous Sclerosis
1
Thyroid Cancer, Papillary
1
Pituitary Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Insulinoma
1
Hyperinsulinism
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Congenital Hyperinsulinism
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Advanced Extrapulmonary Neuroendocrine Cancer
1
Adenocarcinoma, Follicular
1
Acromegaly
1
Interventions
Everolimus
6
Sunitinib
4
Octreotide
4
Leucovorin
4
dabrafenib
3
Fluorouracil
3
3-Iodobenzylguanidine
3
trametinib
2
selpercatinib
2
lutetium Lu 177 dotatate
2
avelumab
2
alectinib
2
PM 01183
2
Oxaliplatin
2
Irinotecan
2
Fulvestrant
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
trifluridine tipiracil drug combination
1
tipifarnib
1
telotristat ethyl
1
surufatinib
1
somapacitan
1
ribociclib
1
repotrectinib
1
pralsetinib
1
pentetreotide
1
pegfilgrastim
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Injections
×
Endocrine
×
Clear all
NCT04837885
2025-07-23
LUTARTERIAL
University Hospital, Bordeaux
Phase 2
Recruiting
23 enrolled